ArticleEuropean journal of medical research2025
LncRNA Rmst-driven DNMT3A mRNA stabilization through HuR: implications for neuropathic pain therapy.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LncRNA RNF144A-AS1 increases P300-mediated H4K5 acetylation of PDE4 to promote keloid fibrosis.Biomedical engineering online · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aimed to explore the role of lncRNA Rmst in regulating DNA methyltransferase 3A (DNMT3A) expression and its impact on neuropathic pain (NP).
methodsA SAM-based lncRNA library screening system was employed to identify lncRNAs regulating DNMT3a stability. Spared nerve injury (SNL) and chronic constriction injury (CCI) rat models of neuropathic pain were established. LncRNA Rmst was knocked down in injured dorsal root ganglia via microinjection of siRmst. Lentiviral vectors carrying siRmst or pcDNA-DNMT3A were constructed and injected into mouse spinal cords. Analyses included qRT-PCR, Western blot, in situ hybridization, immunofluorescence, dual-luciferase reporter assays, and RNA immunoprecipitation (RIP). Pain-related behaviors were assessed using behavioral tests.
resultsWe identified 121 lncRNAs that could enhance DNMT3A stability, and Rmst was among the five lncRNAs significantly upregulated in the neuropathic pain model. In SNL and CCI rat models, knockdown of Rmst led to downregulation of DNMT3A expression, reduced neuronal excitability, inhibited microglial activation, and decreased release of inflammatory factors. The expression of DNMT3A increased over time in both models, and it was positively correlated with Rmst. Mechanistically, Rmst interacted with the -RNA-binding protein HuR to stabilize DNMT3A mRNA. Overexpression of DNMT3A in mice increased pain sensitivity, pro-inflammatory cytokine expression, and microglial activation.
conclusionsLncRNA Rmst binds to HuR to enhance the stability of DNMT3A mRNA, thereby facilitating neuropathic pain progression. Targeting the Rmst-HuR-DNMT3A axis could represent a promising therapeutic approach for neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.